Hepatitis C treatment: latest news

Hepatitis C treatment resources

  • Hepatitis C

    A blood test for antibodies will show if you have been exposed to hepatitis C.HIV treatment has particular benefits for people with HIV and hepatitis...

    From: Factsheets

    Information level Level 2
  • Hepatitis C treatment

    Effective treatments are available for hepatitis C. This field is evolving rapidly and standards of care are changing. The newest drugs can cure most people with hepatitis...

    From: Booklets

    Information level Level 2
  • Medications for hepatitis C

    The old standard of care for hepatitis C treatment for all HCV genotypes was pegylated interferon and ribavirin. Interferon works by stimulating immune system activity against HCV. There...

    From: Booklets

    Information level Level 2
  • Hepatitis C treatment for people with co-infection

    Current guidelines recommend that you start hepatitis C treatment if you have HIV and HCV co-infection with moderate or worse liver fibrosis (stage F2 to F4) and...

    From: Booklets

    Information level Level 2
  • Hepatitis C

    Hepatitis C is a serious infection caused by a virus.It damages the liver, which performs essential functions in the body.Some people have hepatitis C for...

    From: The basics

    Information level Level 1
  • Hepatitis C treatment

    Deciding on the best time to take treatment for hepatitis C is not straightforward.It’s important to get support and advice to help you with this...

    From: The basics

    Information level Level 1

Hepatitis C treatment features

Hepatitis C treatment in your own words

Hepatitis C treatment news from aidsmap

More news

Hepatitis C treatment news selected from other sources

  • Top 10 Pharmaceutical Companies 2017

    The global pharmaceutical market was estimated in USD 1.1 trillion in 2016. The top ten pharmaceutical companies in this market had share of around 40% in 2016 and the top 15 approximately 50%. A comparative analysis of the top 15 organisations was used to develop a ranking for these companies. The analysis shows that by far the biggest earners in terms of classes of drugs were oncology drugs and related immune-modulators. Two of the top ten companies featured hepatitis C drugs in their largest earners and one (Gilead) HIV drugs. The HPV vaccine Gardasil also made a lot of money for its developers Merck.

    18 April 2017 | LinkedIn
  • Hepatitis drug patent application opposed

    A health advocacy group voiced its opposition Tuesday to a patent application for hepatitis C medicine, Sofosbuvir, filed with the Department of Intellectual Property's Patent Office, which the group said was unjustified. If approved, the drug patent would bar fair competition by precluding the development and distribution of generic versions of Sofosbuvir at lower prices, said a group of 30 activists led by the Aids Access Foundation and Thai Network of People Living with HIV/Aids.

    12 April 2017 | Bangkok Post
  • WHO prequalifies first generic active ingredient for hepatitis C medicines

    On 31 March 2017, WHO for the first time prequalified a generic active pharmaceutical ingredient (API) for hepatitis C – sofosbuvir. Sofosbuvir is an essential ingredient for new, highly effective medicines to treat hepatitis C called direct active antivirals (DAAs). The prequalified product’s manufacturer is Mylan Laboratories Ltd - India.

    05 April 2017 | World Health Organization
  • Scale up of hepatitis C treatment possible as Brazil rejects patent on key drug

    Treatment for hepatitis C using the key drug sofosbuvir could be vastly scaled up in Brazil after the decision by the National Agency of Health Surveillance (Anvisa) to reject a key patent application on the drug marketed by pharmaceutical corporation Gilead. The decision could pave the way to enable generic competition in Brazil, which should lead to price reductions, making it more affordable to scale up treatment.

    03 April 2017 | MSF
  • France Reaches Agreement With Gilead To Drop Prices Of Hepatitis C Treatment

    New prices are expected to come into effect on 1 April. For Sovaldi, it will drop from €41,000 euros to less than €28,700 euros for the treatment of hepatitis C.

    03 April 2017 | Intellectual Property Watch
  • New Report Lays Plan to Eliminate 90,000 Hepatitis B and C Deaths by 2030

    Hepatitis B and C kill more than 20,000 people every year in the United States. A new report from the National Academies of Sciences, Engineering, and Medicine presents a strategy to eliminate these diseases as serious public health problems and prevent nearly 90,000 deaths by 2030.

    29 March 2017 | National Academies of Science. Technology and Engineering
  • The 2017 Hepatitis C Community Summit – a key step on the road to elimination

    In the lead-up to the annual International Liver Congress (ILC) in Amsterdam, Eberhard Schatz of the Correlation Network writes about the Hepatitis C Community Summit that will be held in Amsterdam on the 18-19th of April to focus on community-related initiatives and their key role in the hepatitis C elimination movement. Read more about the Summit and register here.

    27 March 2017 | BMC Blogs Network (blog)
  • Gilead hepatitis C drug patent faces European challenge

    International groups representing doctors and patients have launched a fresh challenge to the patent on Gilead Sciences' hepatitis C drug sofosbuvir at the European Patent Office in order to increase access to the treatment.

    27 March 2017 | Reuters
  • Pharma could take NHS England to court over new delaying tactics

    Pharma and patient groups are dismayed by new cost-capping and delaying measures, which they say will further restrict access to new medicines in England.

    27 March 2017 | PharmaPhorum
  • Optimism About HCV Treatment Comes With Caveats

    Despite significant advances in treatment for individuals with HCV infection, several important issues prevail in this patient population.

    22 March 2017 | Medscape
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.